Comparison of the lipid-lowering effect of clofibrate, and of clofibrate plus beta-pyridylcarbinol.
Forty-eight patients under 65 years were included in a double blind study comparing the lipid-lowering effect of clofibrate with that of beta-pyridylcarbinol combined with clofibrate. Over 4 months there was no significant difference in the lipid-lowering effect of either regime. A mean reduction of triglyceride of approximately 30% and of cholesterol of 18% was observed. Both drugs caused significantly greater reductions than placebo. No serious side-effects were noted.
D000704:Analysis of Variance; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009540:Nicotinyl Alcohol / Q000627:therapeutic use*; D010919:Placebos; D011725:Pyridines / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D010919:Placebos; D011725:Pyridines; D014280:Triglycerides; D002784:Cholesterol; D009540:Nicotinyl Alcohol; D002994:Clofibrate